Abstract

*Aryan P. Nimkar, Dr. Nitin Kohale, Prof. Suraj Yadav, Prof. Sonam Bisen and Dr. Harigopal S. Sawarkar

ABSTRACT

Biologic drugs have emerged as a groundbreaking innovation in the treatment of chronic diseases, offering highly targeted therapies that improve patient outcomes and quality of life. Unlike traditional small-molecule drugs, biologics are derived from living organisms and are specifically designed to target molecular mechanisms underlying conditions like rheumatoid arthritis, diabetes, cancer, and inflammatory bowel disease. This paper explores the development, mechanisms, and applications of biologics, emphasizing their advantages over conventional treatments. However, challenges such as high costs, manufacturing complexity, and accessibility are significant barriers to widespread use. Regulatory and ethical considerations, including the approval of bio similars and equitable distribution, are also analyzed. Looking ahead, advancements in gene editing, personalized medicine, and nanotechnology promise to address these challenges, ensuring biologics continue to revolutionize chronic disease management.